Takahashi Masato相关文献与解析，生知库 | 链接生命科学的每一步

Takahashi, Masato; Mukai, Hirofumi; Takano, Toshimi; Tsugawa, Koichiro; Inoue, Kenichi; Itoh, Mitsuya; Watanabe, Junichiro; Tanabe, Yuko; Yamamoto, Naohito; Miyoshi, Yasuo; Watanabe, Kenichi; Mukohara, Toru; Kong, Yibin; Shimura, Masashi; Beca, Francisco; Schmid, Peter; Iwata, Hiroji

肿瘤

肿瘤免疫

乳腺癌

发表日期：2026

文献求助收藏

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

根据同源重组缺陷状态分层的三阴性乳腺癌患者接受基于艾立布林的新辅助化疗的长期疗效：随机JBCRG-22研究的结果

期刊:Breast Cancer Research and Treatment

影响因子:3

doi:10.1007/s10549-026-07917-5

Masuda, Norikazu; Yasojima, Hiroyuki; Bando, Hiroko; Yamanaka, Takashi; Shigematsu, Hideo; Takahashi, Masato; Nagai, Shigenori E; Ito, Mitsuya; Aruga, Tomoyuki; Tokiwa, Mariko; Imoto, Shigeru; Nakamura, Rikiya; Ishiguro, Hiroshi; Kawabata, Hidetaka; Saji, Shigehira; Haga, Hironori; Morita, Satoshi; Toi, Masakazu

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

曲妥珠单抗-帕妥珠单抗联合艾立布林或紫杉烷类药物作为人表皮生长因子2阳性局部晚期/转移性乳腺癌的一线化疗方案：随机非劣效性III期EMERALD试验

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO-24-01888

Yamashita, Toshinari; Saji, Shigehira; Takano, Toshimi; Naito, Yoichi; Tsuneizumi, Michiko; Yoshimura, Akiyo; Takahashi, Masato; Tsurutani, Junji; Iwatani, Tsuguo; Kitada, Masahiro; Tada, Hiroshi; Mori, Natsuko; Higuchi, Toru; Iwasa, Tsutomu; Araki, Kazuhiro; Koizumi, Kei; Hasegawa, Hiroki; Uchida, Yohei; Morita, Satoshi; Masuda, Norikazu

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO-24-01673

Yamamoto, Yutaka; Iwata, Hiroji; Saji, Shigehira; Takahashi, Masato; Yoshinami, Tetsuhiro; Ueno, Takayuki; Toyama, Tatsuya; Yamanaka, Takashi; Takano, Toshimi; Kashiwaba, Masahiro; Tsugawa, Koichiro; Hasegawa, Yoshie; Tamura, Kenji; Tada, Hiroshi; Hara, Fumikata; Fujisawa, Tomomi; Niikura, Naoki; Taira, Naruto; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji; Masuda, Norikazu

Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

更正：帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO-25-00722

Artificial intelligence can extract important features for diagnosing axillary lymph node metastasis in early breast cancer using contrast-enhanced ultrasonography

人工智能可以利用对比增强超声技术提取重要特征，用于诊断早期乳腺癌腋窝淋巴结转移。

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-025-90099-9

Oshino, Tomohiro; Enda, Ken; Shimizu, Hirokazu; Sato, Megumi; Nishida, Mutsumi; Kato, Fumi; Oda, Yoshitaka; Hosoda, Mitsuchika; Kudo, Kohsuke; Iwasaki, Norimasa; Tanaka, Shinya; Takahashi, Masato

Impact of breast tumor size discrepancy between contrast-enhanced and conventional ultrasonography on axillary node metastasis: a retrospective cohort study

增强超声与常规超声检查中乳腺肿瘤大小差异对腋窝淋巴结转移的影响：一项回顾性队列研究

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-15167-9

Oshino, Tomohiro; Shimizu, Hirokazu; Sato, Megumi; Nishida, Mutsumi; Horie, Tatsunori; Tsuneta, Satonori; Kato, Fumi; Hosoda, Mitsuchika; Yokota, Isao; Kudo, Kohsuke; Takahashi, Masato

Association between decreased taurine levels in the anterior cingulate cortex and restricted and repetitive behaviors in autism spectrum disorder: a cross-sectional study

前扣带回皮层牛磺酸水平降低与自闭症谱系障碍患者的局限性和重复性行为之间的关联：一项横断面研究

期刊:Frontiers in Psychiatry

影响因子:3.2

doi:10.3389/fpsyt.2025.1700059

Minami, Akihiro; Matsuoka, Kiwamu; Takahashi, Masato; Ueda, Kazuya; Ohnishi, Hiroki; Fujimoto, Yuka; Yoshikawa, Hiroaki; Ishida, Rio; Takado, Yuhei; Near, Jamie; Yamatani, Yuya; Miyasaka, Toshiteru; Tai, Yumi; Ochi, Tomoko; Tanaka, Toshihiro; Okada, Takashi; Iwata, Nakao; Makinodan, Manabu

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

一线治疗帕博西尼联合来曲唑治疗ER+/HER2-晚期乳腺癌日本患者的总生存期和后续治疗模式：最终分析

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-025-01760-0

Takahashi, Masato; Yasojima, Hiroyuki; Osako, Tomofumi; Inoue, Kenichi; Kawashima, Masahiro; Maeda, Hideki; Ito, Mitsuya; Sagara, Yasuaki; Yonemori, Kan; Hattori, Masaya; Yamamoto, Naohito; Muramatsu, Yasuaki; Matsui, Akiko; Masuda, Norikazu

Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database

利用日本遗传性乳腺癌和卵巢癌联盟（HBOC）以及日本遗传性乳腺癌和卵巢癌组织（JOHBOC）登记项目数据库，分析对乳腺癌女性进行BRCA基因检测的条件。

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-025-01704-8

Takahashi, Masato; Minoura, Yuko; Den, Hiroki; Nomizu, Tadashi; Ishida, Takanori; Kumamaru, Hiraku; Arai, Masami; Nakamura, Seigo

Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis

帕博利珠单抗治疗早期三阴性乳腺癌：KEYNOTE-522 日本亚组分析

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

根据同源重组缺陷状态分层的三阴性乳腺癌患者接受基于艾立布林的新辅助化疗的长期疗效：随机JBCRG-22研究的结果

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

曲妥珠单抗-帕妥珠单抗联合艾立布林或紫杉烷类药物作为人表皮生长因子2阳性局部晚期/转移性乳腺癌的一线化疗方案：随机非劣效性III期EMERALD试验

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

更正：帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

Artificial intelligence can extract important features for diagnosing axillary lymph node metastasis in early breast cancer using contrast-enhanced ultrasonography

人工智能可以利用对比增强超声技术提取重要特征，用于诊断早期乳腺癌腋窝淋巴结转移。

Impact of breast tumor size discrepancy between contrast-enhanced and conventional ultrasonography on axillary node metastasis: a retrospective cohort study

增强超声与常规超声检查中乳腺肿瘤大小差异对腋窝淋巴结转移的影响：一项回顾性队列研究

Association between decreased taurine levels in the anterior cingulate cortex and restricted and repetitive behaviors in autism spectrum disorder: a cross-sectional study

前扣带回皮层牛磺酸水平降低与自闭症谱系障碍患者的局限性和重复性行为之间的关联：一项横断面研究

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

一线治疗帕博西尼联合来曲唑治疗ER+/HER2-晚期乳腺癌日本患者的总生存期和后续治疗模式：最终分析

Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database

利用日本遗传性乳腺癌和卵巢癌联盟（HBOC）以及日本遗传性乳腺癌和卵巢癌组织（JOHBOC）登记项目数据库，分析对乳腺癌女性进行BRCA基因检测的条件。